Intellia to Release HAELO Trial Results in April 2026
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy NTLA?
Source: NASDAQ.COM
- Clinical Milestone: Intellia Therapeutics is set to release topline results from its global Phase 3 HAELO clinical trial on April 27, 2026, marking the world's first Phase 3 readout for an in vivo CRISPR gene-editing candidate, potentially offering new treatment options for rare disease patients.
- Treatment Objective: The HAELO study aims to evaluate the efficacy of Lonvoguran ziclumeran as a one-time in vivo CRISPR therapy, targeting a reduction in the frequency and severity of hereditary angioedema (HAE) attacks, thereby addressing the underlying genetic cause and meeting patients' urgent need for long-term prevention.
- Market Reaction: On April 24, 2026, NTLA stock closed at $13.63, down 14.11% from the previous trading day, but surged 19.27% in after-hours trading to $16.26, reflecting positive market sentiment ahead of the upcoming clinical data release.
- Company Strategy: Intellia is focused on developing therapies that directly edit disease-causing genes within the body, and the results from the HAELO trial will provide crucial support for its broader mission, reinforcing its leadership position in the gene-editing sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NTLA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NTLA
Wall Street analysts forecast NTLA stock price to rise
22 Analyst Rating
9 Buy
12 Hold
1 Sell
Moderate Buy
Current: 13.630
Low
4.00
Averages
16.50
High
54.00
Current: 13.630
Low
4.00
Averages
16.50
High
54.00
About NTLA
Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on developing medicine with CRISPR-based therapies and other core technologies. CRISPR/Cas9 is a gene editing technology that leverages the body’s natural processes to precisely edit DNA. The Company is developing lonvoguran ziclumeran (lonvo-z), referred to as NTLA-2002, for the treatment of hereditary angioedema (HAE) and nexiguran ziclumeran (nex-z) also referred to as NTLA-2001, for the treatment of transthyretin (ATTR) amyloidosis. It is focused on completing late-stage clinical development of its lead product candidates, lonvo-z for the treatment of patients with HAE and nex-z for the treatment of patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM) and hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN). Its lead product candidates are the first in vivo genome editing product candidates into Phase III development. Its other pipeline products include REGV131-LNP1265 and AVC-201 & AVC-203.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intellia Initiates BLA Submission for Lonvo-z in HAE Treatment
- BLA Submission Initiated: Intellia Therapeutics has begun the rolling submission of a Biologics License Application (BLA) to the FDA for lonvo-z, aimed at providing a one-time treatment for hereditary angioedema (HAE), which, if approved, would be the world's first CRISPR-based gene editing therapy.
- Clinical Trial Success: The Phase 3 HAELO trial of lonvo-z met its primary and all key secondary endpoints, demonstrating that most patients experienced freedom from HAE attacks and ongoing therapy needs during the six-month observation period, indicating its potential revolutionary impact on treatment.
- Expedited Review Pathway: With the FDA granting lonvo-z the Regenerative Medicine Advanced Therapy (RMAT) designation, Intellia can submit portions of the BLA on an ongoing basis, anticipating completion in the second half of 2026, and if approved, plans to commercially launch in the first half of 2027, significantly enhancing patient access to treatment.
- Regulatory Designations: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its potential in treating HAE and the possibility of improving patients' quality of life while reducing reliance on long-term therapies.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 22.14 points to 27,281.53, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Organon & Co. (OGN) rises by $1.91 to $13.17 with a trading volume of 34,420,118 shares, currently priced at 146.33% of its target price, reflecting optimistic market expectations for its future performance.
- Earnings Forecast: Intel Corporation (INTC) has had three upward revisions in earnings forecasts over the past four weeks, with a current stock price of $82.86 and an expected EPS of $0.08 for the fiscal quarter ending June 2027, showcasing market confidence in its future profitability.
- Short Interest Data: Sagimet Biosciences Inc. (SGMT) and Intellia Therapeutics, Inc. (NTLA) have days to cover of 10.41 and 15.42 respectively, indicating high short-term trading activity for these stocks, which may impact their price volatility.
See More
Intellia Achieves Breakthrough in Rare Genetic Condition Treatment
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated a remarkable efficacy in its Phase 3 trial, with 62% of patients completely free of HAE attacks over six months, compared to just 11% in the placebo group, indicating a potential paradigm shift in treatment for this rare genetic condition.
- FDA Application Initiated: The company has commenced a rolling Biologics License Application submission to the U.S. FDA, with plans for a potential U.S. launch of lonvo-z in the first half of 2027, which could open significant market opportunities and revenue streams for Intellia.
- Positive Market Reaction: Intellia's shares surged over 9% in pre-market trading on Monday, making it the top trending stock, reflecting strong investor optimism about lonvo-z, with a year-to-date increase of 52% in stock price.
- Significant Patient Impact: As a one-time treatment, lonvo-z aims to permanently reduce kallikrein and bradykinin levels through CRISPR gene editing, offering new hope for patients who have long suffered from HAE, potentially improving their quality of life significantly.
See More
Intellia's Gene Editing Therapy Trial Achieves Success
- Clinical Trial Success: Intellia Therapeutics' gene editing therapy achieved an 87% reduction in attacks during late-stage trials, significantly surpassing the placebo group, marking a crucial milestone in gene editing and paving the way for FDA approval.
- Positive Patient Outcomes: Six months post-treatment, 62% of patients were attack-free and not using other therapies, demonstrating the therapy's efficacy and durability, which could transform treatment paradigms for hereditary angioedema patients.
- Favorable Safety Profile: Despite a patient death in a separate trial due to liver toxicity, Intellia reported a favorable safety and tolerability profile for its therapy, with common side effects being infusion-related reactions, headaches, and fatigue, bolstering market confidence.
- Market Competition Outlook: If approved by the FDA, Intellia's lonvoguran ziclumeran will compete with other chronic drugs, and while the commercial success of gene therapies has been mixed, the potential for a one-time treatment continues to attract investor interest.
See More
Stock Index Futures Dip as Big Tech Earnings Approach Amid U.S.-Iran Uncertainty
- Intellia Stock Surge: Intellia Therapeutics shares jumped 25% as anticipation builds for its upcoming Phase 3 clinical trial results for hereditary angioedema, reflecting investor optimism around its CRISPR-based therapy, which could significantly impact future stock performance.
- Organon Acquisition Deal: Sun Pharmaceutical Industries agreed to acquire Organon for approximately $11.75 billion in an all-cash deal, with shareholders set to receive $14 per share, expected to close in early 2027, thereby strengthening Sun Pharma's position in women's health and biosimilars.
- Qualcomm Partnership Prospects: Qualcomm shares rose 10% following reports that OpenAI is exploring partnerships with Qualcomm and MediaTek for smartphone processors, with mass production not expected until 2028, indicating potential long-term demand support for Qualcomm's next-gen mobile chips.
- GE Vernova Downgrade: GE Vernova shares fell 2% after BNP Paribas downgraded the stock to Neutral, citing limited visibility on sustaining growth as 90% of gas turbine capacity is contracted through 2030, raising concerns about execution risk and capacity expansion, impacting market sentiment.
See More
Trump Cancels Diplomatic Mission to Pakistan Amid Geopolitical Tensions
- Diplomatic Mission Canceled: President Trump abruptly scrapped plans for a diplomatic mission to Pakistan due to infighting in Tehran, a move that could escalate tensions in the Middle East and impact U.S. foreign policy strategies in the region.
- Iran's New Proposal: Iran floated a proposal to reopen the Strait of Hormuz in exchange for delaying nuclear talks, which could significantly affect the stability of global energy markets and geopolitical dynamics.
- Stock Market Outlook Dim: U.S. stock futures fell early Monday amid rising geopolitical tensions, with retail sentiment for the SPDR S&P 500 ETF shifting from 'bullish' to 'neutral', indicating investor uncertainty about future market conditions.
- Key Earnings Reports Ahead: This week, major tech companies including Amazon, Microsoft, Meta, Alphabet, and Apple are set to report earnings, with market participants closely monitoring these results for their potential impact on tech stocks amid high inflation and upcoming Federal Reserve decisions.
See More
Intellia Initiates BLA Submission for Lonvo-z in HAE Treatment
- BLA Submission Initiated: Intellia Therapeutics has begun the rolling submission of a Biologics License Application (BLA) to the FDA for lonvo-z, aimed at providing a one-time treatment for hereditary angioedema (HAE), which, if approved, would be the world's first CRISPR-based gene editing therapy.
- Clinical Trial Success: The Phase 3 HAELO trial of lonvo-z met its primary and all key secondary endpoints, demonstrating that most patients experienced freedom from HAE attacks and ongoing therapy needs during the six-month observation period, indicating its potential revolutionary impact on treatment.
- Expedited Review Pathway: With the FDA granting lonvo-z the Regenerative Medicine Advanced Therapy (RMAT) designation, Intellia can submit portions of the BLA on an ongoing basis, anticipating completion in the second half of 2026, and if approved, plans to commercially launch in the first half of 2027, significantly enhancing patient access to treatment.
- Regulatory Designations: Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT designations from the FDA, highlighting its potential in treating HAE and the possibility of improving patients' quality of life while reducing reliance on long-term therapies.
See More
NASDAQ 100 Pre-Market Activity Overview
- Market Performance: The NASDAQ 100 Pre-Market Indicator is down 22.14 points to 27,281.53, indicating cautious market sentiment that may influence short-term investor decisions.
- Active Stocks: Organon & Co. (OGN) rises by $1.91 to $13.17 with a trading volume of 34,420,118 shares, currently priced at 146.33% of its target price, reflecting optimistic market expectations for its future performance.
- Earnings Forecast: Intel Corporation (INTC) has had three upward revisions in earnings forecasts over the past four weeks, with a current stock price of $82.86 and an expected EPS of $0.08 for the fiscal quarter ending June 2027, showcasing market confidence in its future profitability.
- Short Interest Data: Sagimet Biosciences Inc. (SGMT) and Intellia Therapeutics, Inc. (NTLA) have days to cover of 10.41 and 15.42 respectively, indicating high short-term trading activity for these stocks, which may impact their price volatility.
See More
Intellia Achieves Breakthrough in Rare Genetic Condition Treatment
- Clinical Trial Success: Intellia Therapeutics' lonvo-z demonstrated a remarkable efficacy in its Phase 3 trial, with 62% of patients completely free of HAE attacks over six months, compared to just 11% in the placebo group, indicating a potential paradigm shift in treatment for this rare genetic condition.
- FDA Application Initiated: The company has commenced a rolling Biologics License Application submission to the U.S. FDA, with plans for a potential U.S. launch of lonvo-z in the first half of 2027, which could open significant market opportunities and revenue streams for Intellia.
- Positive Market Reaction: Intellia's shares surged over 9% in pre-market trading on Monday, making it the top trending stock, reflecting strong investor optimism about lonvo-z, with a year-to-date increase of 52% in stock price.
- Significant Patient Impact: As a one-time treatment, lonvo-z aims to permanently reduce kallikrein and bradykinin levels through CRISPR gene editing, offering new hope for patients who have long suffered from HAE, potentially improving their quality of life significantly.
See More
Intellia's Gene Editing Therapy Trial Achieves Success
- Clinical Trial Success: Intellia Therapeutics' gene editing therapy achieved an 87% reduction in attacks during late-stage trials, significantly surpassing the placebo group, marking a crucial milestone in gene editing and paving the way for FDA approval.
- Positive Patient Outcomes: Six months post-treatment, 62% of patients were attack-free and not using other therapies, demonstrating the therapy's efficacy and durability, which could transform treatment paradigms for hereditary angioedema patients.
- Favorable Safety Profile: Despite a patient death in a separate trial due to liver toxicity, Intellia reported a favorable safety and tolerability profile for its therapy, with common side effects being infusion-related reactions, headaches, and fatigue, bolstering market confidence.
- Market Competition Outlook: If approved by the FDA, Intellia's lonvoguran ziclumeran will compete with other chronic drugs, and while the commercial success of gene therapies has been mixed, the potential for a one-time treatment continues to attract investor interest.
See More
Stock Index Futures Dip as Big Tech Earnings Approach Amid U.S.-Iran Uncertainty
- Intellia Stock Surge: Intellia Therapeutics shares jumped 25% as anticipation builds for its upcoming Phase 3 clinical trial results for hereditary angioedema, reflecting investor optimism around its CRISPR-based therapy, which could significantly impact future stock performance.
- Organon Acquisition Deal: Sun Pharmaceutical Industries agreed to acquire Organon for approximately $11.75 billion in an all-cash deal, with shareholders set to receive $14 per share, expected to close in early 2027, thereby strengthening Sun Pharma's position in women's health and biosimilars.
- Qualcomm Partnership Prospects: Qualcomm shares rose 10% following reports that OpenAI is exploring partnerships with Qualcomm and MediaTek for smartphone processors, with mass production not expected until 2028, indicating potential long-term demand support for Qualcomm's next-gen mobile chips.
- GE Vernova Downgrade: GE Vernova shares fell 2% after BNP Paribas downgraded the stock to Neutral, citing limited visibility on sustaining growth as 90% of gas turbine capacity is contracted through 2030, raising concerns about execution risk and capacity expansion, impacting market sentiment.
See More
Trump Cancels Diplomatic Mission to Pakistan Amid Geopolitical Tensions
- Diplomatic Mission Canceled: President Trump abruptly scrapped plans for a diplomatic mission to Pakistan due to infighting in Tehran, a move that could escalate tensions in the Middle East and impact U.S. foreign policy strategies in the region.
- Iran's New Proposal: Iran floated a proposal to reopen the Strait of Hormuz in exchange for delaying nuclear talks, which could significantly affect the stability of global energy markets and geopolitical dynamics.
- Stock Market Outlook Dim: U.S. stock futures fell early Monday amid rising geopolitical tensions, with retail sentiment for the SPDR S&P 500 ETF shifting from 'bullish' to 'neutral', indicating investor uncertainty about future market conditions.
- Key Earnings Reports Ahead: This week, major tech companies including Amazon, Microsoft, Meta, Alphabet, and Apple are set to report earnings, with market participants closely monitoring these results for their potential impact on tech stocks amid high inflation and upcoming Federal Reserve decisions.
See More
